Compare IBEX & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | BNTC |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 411.4M |
| IPO Year | 2017 | 2020 |
| Metric | IBEX | BNTC |
|---|---|---|
| Price | $27.24 | $10.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $35.00 | $27.67 |
| AVG Volume (30 Days) | 95.9K | ★ 168.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.26 | ★ 80.94 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $558,273,000.00 | N/A |
| Revenue This Year | $13.14 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | $16.95 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $21.64 | $9.85 |
| 52 Week High | $42.99 | $17.15 |
| Indicator | IBEX | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 42.84 |
| Support Level | N/A | $10.10 |
| Resistance Level | $30.14 | $13.06 |
| Average True Range (ATR) | 0.92 | 0.79 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 3.39 | 20.67 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.